New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application ("the application") for its trophoblast cell-surface antigen 2 ...

Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA

Zydus Lifesciences Limited (Zydus), an innovation-led global life-sciences company, and Formycon AG (Formycon), an independent developer of biosimilars, today jointly announced that the US Food and ...
Yahoo Finance

GSK's Jemperli (dostarlimab) accepted for review by Health Canada for patients with dMMR/MSI-H locally advanced rectal cancer

Submission supported by AZUR-1 data showing a significant proportion of participants had no detectable signs of cancer one year or more after treatment completion If approved, Jemperli could ...
MarketScreener

Kelun-Biotech Lung Cancer Drug Accepted for Review for New Indication in China

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of drugs. The Company is mainly e ...